Date of Award

Summer 6-14-2024

Document Type

Open Access Thesis

Degree Name

Master of Medical Science (MMSc)

First Advisor

Timothy Belliveau, PhD, ABPP

Abstract

Selective head-neck cooling therapy as novel treatment for concussion has been researched in pilot studies for several years using symptom severity as the primary outcome. As of 2018, brain biomarkers glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) have been FDA approved as indicators of Traumatic Brain Injury (TBI). This study aims to investigate the effects of selective head-neck cooling therapy on the serum levels of the biomarkers, alongside patient symptom severity, in adults aged 18 years and older with mild Traumatic Brain Injury diagnosed in the last 72 hours. A randomized controlled trial will compare two intervention groups receiving selective head and neck cooling therapy for 30 minutes daily and 30 minutes every other day for 10 days, along with a control group receiving standard of care. This study seeks to fill a gap in the literature by exploring potential anti-neuroinflammatory effects of selective head-neck cooling therapy.

Comments

This is an open access thesis.

Open Access

This Article is Open Access

Share

COinS